COSCIENS Biopharma Inc.
No enriched coverage for $CSCIF in the last 7 days.
No SEC Form 4 filings for $CSCIF in the last 30 days.
See all $CSCIF insider activity →COSCIENS Biopharma Inc. (TSX: CSCI, OTCQB: CSCI.F) reported Q2 2026 results for the quarter ended June 30, 2026. It had $5.3 million cash, Q2 net loss of $0.2 million ($0.19 per share) versus $2.7 million in Q2 2025, and Q2 revenue of $3.1 million. First-half net income was $10.6 million. The company also approved a share reorganization to file Form 15F and suspend SEC reporting.
COSCIENS Biopharma Inc. (TSX: CSCI; OTCQB: CSCIF) said its share capital amendment took effect July 3, 2026: a 1-for-150 share consolidation followed by a 50-for-1 split. Holders with <150 shares received US$1.60 per share; others received replacement shares. Trading on a post-amendment basis is expected on the TSX within two business days; the company plans a July 6 Form 15 to suspend U.S. reporting.
Recent CSCIF coverage spans corporate actions and financial news.
COSCIENS Biopharma Inc. (TSX: CSCI, OTCQB: CSCI.F) reported Q2 2026 results for the quarter ended June 30, 2026. It had $5.3 million cash, Q2 net loss of $0.2 million ($0.19 per share) versus $2.7 million in Q2 2025, and Q2 revenue of $3.1 million. First-half net income was $10.6 million. The company also approved a share reorganization to file Form 15F and suspend SEC reporting.
OTC holders may see settlement/adjustment effects tied to the same corporate action, potentially impacting spreads and execution quality.
alphai scores every news story that mentions CSCIF with an AI model for sentiment and relevance, and aggregates insider trades from COSCIENS Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
COSCIENS Biopharma Inc. (TSX: CSCI, OTCQB: CSCI.F) reported Q2 2026 results for the quarter ended June 30, 2026. It had $5.3 million cash, Q2 net loss of $0.2 million ($0.19 per share) versus $2.7 million in Q2 2025, and Q2 revenue of $3.1 million. First-half net income was $10.6 million. The company also approved a share reorganization to file Form 15F and suspend SEC reporting.
4 min readCOSCIENS Biopharma Inc. (TSX: CSCI; OTCQB: CSCIF) said its share capital amendment took effect July 3, 2026: a 1-for-150 share consolidation followed by a 50-for-1 split. Holders with <150 shares received US$1.60 per share; others received replacement shares. Trading on a post-amendment basis is expected on the TSX within two business days; the company plans a July 6 Form 15 to suspend U.S. reporting.
3 min read